Brian T. Edelson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Brian T. Edelson has a total of 193 co-authors. Here are the top co-authors by number of shared publications:
- Ana Carolina Paschoalini Mafra
Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri
11 shared publications - Andrew Houston
Washington University in St. Louis 4 Saint Louis, MO
11 shared publications - Cliff Grant Robinson
Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri
11 shared publications - David G. DeNardo
Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA
11 shared publications - Dhaval P. Bhatt
Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri
11 shared publications - Donghua Hu
Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri
11 shared publications
Latest Publications
- 11 May 2026
- Published by Springer Nature
- p. 323-342
Examination of Class I HLA-Fc Fusion Proteins in Targeting Cognate Antibody-Producing Cells
- 11 May 2026
- Published by Springer Nature
- p. 323-342
Examination of Class I HLA-Fc Fusion Proteins in Targeting Cognate Antibody-Producing Cells
- Open Access
- 1 May 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (3) , e200565
Dynamics of Spinal Fluid Immune Cell Alterations Following Cladribine Tablet Treatment in Multiple Sclerosis
Oral cladribine tablet (CladT) therapy is efficacious for relapsing multiple sclerosis (MS). However, the mechanisms by which cladribine exerts benefit in MS remain unclear, particularly regarding its effects on compartmentalized inflammation within the CSF. Transcriptional profiles along with T and B lymphocyte receptor repertoires from CSF and blood were obtained by single-cell sequencing methods from a single site participating in a phase IV clinical trial investigating the impact of cladribine treatment for MS. Blood and CSF samples from patients were obtained immediately before starting CladT therapy, and they were randomized to also provide additional samples at either 5 weeks, 10 weeks, 1 year, or 2 years after CladT therapy. Thirty-four samples from 13 individuals with relapsing MS before and after treatment were available to test the hypothesis that CladT alters the composition and phenotype of lymphocytes in the CSF, including paired baseline and post-CladT CSF samples obtained from 4 unique participants. We found that treatment with CladT profoundly altered cellular composition, but not the transcriptional phenotype, of immune cells in the CSF. In particular, we identified a reduction in switched memory B cells but recovery of naive B cells in the CSF, similar to our findings in blood. In addition, populations of CD4 Treg cells emerged early after CladT therapy and remained elevated 1 year later in the CSF, but not in the blood. Antigen receptor sequencing revealed a moderate decrease in numbers of large clonally expanded CD8 T cell clones (>10 cells/clone) primarily in the CSF, but also in the blood after CladT treatment. Our results identified unique cellular dynamics and changes in T cell and B cell clonality in both tissues, which can potentially explain long-term beneficial effects of CladT therapy in MS, including preservation of immune function and a relatively low number of side effects. Altogether, this study demonstrates that CladT treatment had a substantial impact not only on blood but also on the CSF compartment, highlighting the importance of cross-tissue analysis for better understanding of effect and the mechanism of action of disease-modifying therapies.
- 1 May 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (3) , e200565
Open AccessDynamics of Spinal Fluid Immune Cell Alterations Following Cladribine Tablet Treatment in Multiple Sclerosis
Oral cladribine tablet (CladT) therapy is efficacious for relapsing multiple sclerosis (MS). However, the mechanisms by which cladribine exerts benefit in MS remain unclear, particularly regarding its effects on compartmentalized inflammation within the CSF. Transcriptional profiles along with T and B lymphocyte receptor repertoires from CSF and blood were obtained by single-cell sequencing methods from a single site participating in a phase IV clinical trial investigating the impact of cladribine treatment for MS. Blood and CSF samples from patients were obtained immediately before starting CladT therapy, and they were randomized to also provide additional samples at either 5 weeks, 10 weeks, 1 year, or 2 years after CladT therapy. Thirty-four samples from 13 individuals with relapsing MS before and after treatment were available to test the hypothesis that CladT alters the composition and phenotype of lymphocytes in the CSF, including paired baseline and post-CladT CSF samples obtained from 4 unique participants. We found that treatment with CladT profoundly altered cellular composition, but not the transcriptional phenotype, of immune cells in the CSF. In particular, we identified a reduction in switched memory B cells but recovery of naive B cells in the CSF, similar to our findings in blood. In addition, populations of CD4 Treg cells emerged early after CladT therapy and remained elevated 1 year later in the CSF, but not in the blood. Antigen receptor sequencing revealed a moderate decrease in numbers of large clonally expanded CD8 T cell clones (>10 cells/clone) primarily in the CSF, but also in the blood after CladT treatment. Our results identified unique cellular dynamics and changes in T cell and B cell clonality in both tissues, which can potentially explain long-term beneficial effects of CladT therapy in MS, including preservation of immune function and a relatively low number of side effects. Altogether, this study demonstrates that CladT treatment had a substantial impact not only on blood but also on the CSF compartment, highlighting the importance of cross-tissue analysis for better understanding of effect and the mechanism of action of disease-modifying therapies.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Despite advances in screening and prevention, cervical cancer remains a leading cause of cancer-related deaths worldwide, underscoring the need for better treatments. In this study, we conducted a multicohort longitudinal study of human cervical tumors and the tumor microenvironment during chemoradiotherapy (CRT) and integrated RNA sequencing and single-cell transcriptomics to define the cellular and molecular programs shaping cell interactions and how CRT alters them. The analysis identified multiple therapeutic targets in CRT-resistant tumors, notably including MDM2, a key mediator of radiation responses in tumor and immune cells. MDM2 inhibition enhanced the effects of radiotherapy in human papillomavirus (HPV)–positive, TP53 wild-type cervical cancer cells; improved radiation response; and reshaped the immune landscape in preclinical models. These findings highlight the potential of combining MDM2 inhibition with CRT to overcome resistance and improve patient outcomes. The insights into therapy-induced changes in tumor and immune compartments could guide improved strategies against treatment-resistant HPV-positive cancers.Significance:Mapping of the impact of chemoradiation on cellular interactions in cervical cancer reveals how treatment reshapes the tumor microenvironment and highlights targets for developing future immunotherapeutic approaches.See related commentary by Klopp, p. 1540
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Despite advances in screening and prevention, cervical cancer remains a leading cause of cancer-related deaths worldwide, underscoring the need for better treatments. In this study, we conducted a multicohort longitudinal study of human cervical tumors and the tumor microenvironment during chemoradiotherapy (CRT) and integrated RNA sequencing and single-cell transcriptomics to define the cellular and molecular programs shaping cell interactions and how CRT alters them. The analysis identified multiple therapeutic targets in CRT-resistant tumors, notably including MDM2, a key mediator of radiation responses in tumor and immune cells. MDM2 inhibition enhanced the effects of radiotherapy in human papillomavirus (HPV)–positive, TP53 wild-type cervical cancer cells; improved radiation response; and reshaped the immune landscape in preclinical models. These findings highlight the potential of combining MDM2 inhibition with CRT to overcome resistance and improve patient outcomes. The insights into therapy-induced changes in tumor and immune compartments could guide improved strategies against treatment-resistant HPV-positive cancers.Significance:Mapping of the impact of chemoradiation on cellular interactions in cervical cancer reveals how treatment reshapes the tumor microenvironment and highlights targets for developing future immunotherapeutic approaches.See related commentary by Klopp, p. 1540
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Singe-cell expression matrix for custom clustering annotation related to Figure 2A
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Singe-cell expression matrix for custom clustering annotation related to Figure 2A
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Top 5 gene ontology pathways enriched in each cell type upon chemoradiation related to Figure 3D
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Top 5 gene ontology pathways enriched in each cell type upon chemoradiation related to Figure 3D
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 5
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 5
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 4
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 4
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 2
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 2
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 3
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 3